

TECHNICAL DATA SHEET

CyFlow™ HLA-A2 Alexa Fluor™ 488 Anti-Hu; Clone BB7.2

REF BS119230

For Research Use Only.
Not for use in diagnostic or therapeutic procedures.

Specifications

Antigen	HLA-A2
Alternative Names	—
Clone	BB7.2
Clonality	monoclonal
Format	Alexa Fluor™ 488
Host / Isotype	Mouse / IgG2b
Species Reactivity	Human
Negative Species Reactivity	—
Quantity	100 tests
Immunogen	HLA-A2 solubilised by papain

Specificity

The mouse monoclonal antibody BB7.2 recognizes an epitope at the C-terminus of α -2 helix and a turn on one of the underlying β strands within the human HLA-A2 histocompatibility antigen.

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com

Application

The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4 µl reagent / 100 µl of whole blood or 10⁶ cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.

Other usages may be determined from the scientific literature.

Storage Buffer

The reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.1% (w/v) sodium azide.

Storage and Stability

Storage	Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
Stability	Do not use after expiration date stamped on vial label.

Background Information

HLA-A2 (44 kDa) is the most frequent HLA-A allele in human ethnic populations. HLA-A, together with HLA-B and HLA-C, represent human HLA class I major histocompatibility (MHC) antigens. These intrinsic membrane glycoproteins are expressed on nucleated cells and noncovalently associate with an invariant β2-microglobulin. They carry foreign determinants important for immune recognition by cytotoxic T cells, thus important for anti-viral and anti-tumor defense.

References

- Parham P, Brodsky FM: Partial purification and some properties of BB7.2: A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol. 1981 Dec; 3(4):277-99. < PMID: 7035415 >
- Pious D, Krangel MS, Dixon LL, Parham P, Strominger JL: HLA antigen structural gene mutants selected with an allospecific monoclonal antibody. Proc Natl Acad Sci USA. 1982 Dec; 79(24):7832-6. < PMID: 6961455 >
- Taketani S, Krangel MS, Pious D, Strominger JL: Structural analysis of HLA-A2 antigen from immunoselected mutant 8.6.1: further definition of an HLA-A2-specific serological determinant. J Immunol. 1983 Dec; 131(6):2935-8. < PMID: 6196407 >

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com

- Krangel MS, Taketani S, Pious D, Strominger JL: HLA-A2 mutants immunoselected in vitro: Definition of residues contributing to an HLA-A2-specific serological determinant. J Exp Med. 1983 Jan 1; 157(1):324-36. < PMID: 6184441 >
- Brenner MB, McLean J, Yang SY, van der Poel JJ, Pious D, Strominger JL: Clonal T lymphocyte recognition of the fine structure of the HLA-A2 molecule. J Immunol. 1985 Jul; 135(1):384-90. < PMID: 2582041 >
- Scornik JC: HLA-A2 epitopes recognized by alloantibodies from broadly sensitized patients. Hum Immunol. 1987 Apr; 18(4):277-85. < PMID: 2437089 >
- Santos-Aguado J, Barbosa JA, Biro PA, Strominger JL: Molecular characterization of serologic recognition sites in the human HLA-A2 molecule. J Immunol. 1988 Oct 15; 141(8):2811-8. < PMID: 2459229 >
- Natali PG, Nicotra MR, Bigotti A, Ventura I, Marcenaro L, Giacomini P, Russo C: Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci USA. 1989 Sep; 86(17):6719-23. < PMID: 2672003 >
- Hogan KT, Brown SL: Localization and characterization of serologic epitopes on HLA-A2. Hum Immunol. 1992 Mar; 33(3):185-92. < PMID: 1377666 >
- Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D'Amaro J, Kenemans P, Melief CJ, Kast WM: Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol. 1993 Jun; 23(6):1215-9. < PMID: 7684681 >
- Peoples GE, Goedegebuure PS, Andrews JV, Schoof DD, Eberlein TJ: HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol. 1993 Nov 15; 151(10):5481-91. < PMID: 8228240 >
- Barouch D, Davenport M, McMichael A, Reay P: A mAb against HLA-A2 can be influenced both positively and negatively by the associated peptide. Int Immunol. 1995 Oct; 7(10):1599-605. < PMID: 8562505 >
- Lee L, Loftus D, Appella E, Margulies DH, Mage M: A recombinant single-chain HLA-A2.1 molecule, with a cis active beta-2-microglobulin domain, is biologically active in peptide binding and antigen presentation. Hum Immunol. 1996 Aug; 49(1):28-37. < PMID: 8839773 >
- Forero L, Zwirner NW, Fink CW, Fernández-Viña MA, Stastny P: Juvenile arthritis, HLA-A2 and binding of DEK oncogene-peptides. Hum Immunol. 1998 Jul; 59(7):443-50. < PMID: 9684994 >

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
 Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com

- Verdegaaal EM, Huinink DB, Hoogstraten C, Marijnissen AK, Gorsira MB, Claas FH, Osanto S: Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient. Hum Immunol. 1999 Dec; 60(12):1195-206. < PMID: 10626733 >
- Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP: Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol. 2000 Sep; 96(3):422-30. < PMID: 10960637 >
- Liang B, Zhu L, Liang Z, Weng X, Lu X, Zhang C, Li H, Wu X: A simplified PCR-SSP method for HLA-A2 subtype in a population of Wuhan, China. Cell Mol Immunol. 2006 Dec; 3(6):453-8. < PMID: 17257499 >

The Safety Data Sheet for this product is available at www.sysmex-partec.com/services.

This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com.

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com